Evidence map›Paper›PMID 28529483›Full record

ArticleFrontiers in pharmacology2017

Identification of a Novel Allosteric Inhibitory Site on Tryptophan Hydroxylase 1 Enabling Unprecedented Selectivity Over all Related Hydroxylases.

Mike Petrassi, Rob Barber, Celine Be, Sarah Beach, Brian Cox, Anne-Marie D'Souza, Nick Duggan, Martin Hussey, Roy Fox, Peter Hunt and 16 more

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. 4-Arylthiosemicarbazide derivatives as a new class of tyrosinase inhibitors and anti-Journal of enzyme inhibition and medicinal chemistry · 2021
    Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Mike PetrassiGenomics Institute of the Novartis Research Foundation, San DiegoCA, USA.
Rob BarberRespiratory Disease Area, Novartis Institutes for BioMedical ResearchHorsham, UK.
Celine BeNovartis Institutes for BioMedical ResearchBasel, Switzerland.
Sarah BeachRespiratory Disease Area, Novartis Institutes for BioMedical ResearchHorsham, UK.
Brian CoxRespiratory Disease Area, Novartis Institutes for BioMedical ResearchHorsham, UK.
Anne-Marie D'SouzaRespiratory Disease Area, Novartis Institutes for BioMedical ResearchHorsham, UK.
Nick DugganRespiratory Disease Area, Novartis Institutes for BioMedical ResearchHorsham, UK.
Martin HusseyRespiratory Disease Area, Novartis Institutes for BioMedical ResearchHorsham, UK.
Roy FoxRespiratory Disease Area, Novartis Institutes for BioMedical ResearchHorsham, UK.
Peter HuntRespiratory Disease Area, Novartis Institutes for BioMedical ResearchHorsham, UK.
Gabor JaraiRespiratory Disease Area, Novartis Institutes for BioMedical ResearchHorsham, UK.
Takatoshi KosakaRespiratory Disease Area, Novartis Institutes for BioMedical ResearchHorsham, UK.
Paul OakleyRespiratory Disease Area, Novartis Institutes for BioMedical ResearchHorsham, UK.
Viral PatelRespiratory Disease Area, Novartis Institutes for BioMedical ResearchHorsham, UK.
Neil PressRespiratory Disease Area, Novartis Institutes for BioMedical ResearchHorsham, UK.
David RowlandsRespiratory Disease Area, Novartis Institutes for BioMedical ResearchHorsham, UK.
Clemens ScheuflerNovartis Institutes for BioMedical ResearchBasel, Switzerland.
Oliver SchmidtRespiratory Disease Area, Novartis Institutes for BioMedical ResearchHorsham, UK.
Honnappa SrinivasNovartis Institutes for BioMedical ResearchBasel, Switzerland.
Mary TurnerGenomics Institute of the Novartis Research Foundation, San DiegoCA, USA.
Rob TurnerRespiratory Disease Area, Novartis Institutes for BioMedical ResearchHorsham, UK.
John WestwickRespiratory Disease Area, Novartis Institutes for BioMedical ResearchHorsham, UK.
Alison WolfreysRespiratory Disease Area, Novartis Institutes for BioMedical ResearchHorsham, UK.
Nuzhat PathanGenomics Institute of the Novartis Research Foundation, San DiegoCA, USA.
Simon WatsonRespiratory Disease Area, Novartis Institutes for BioMedical ResearchHorsham, UK.
Matthew ThomasRespiratory Disease Area, Novartis Institutes for BioMedical ResearchHorsham, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary arterial hypertension (PAH) has demonstrated multi-serotonin receptor dependent pathologies, characterized by increased tone (5-HT

Indexed as

allosteric bindingpulmonary arterial hypertensionserotonintryptophan

Identifiers

PMID28529483
PMCPMC5418348

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.